Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 86903 

for DPRP recognition is routinely 

collected by most organizations that 

deliver the National DPP lifestyle 

change program for their own internal 

evaluation and possible insurance 

reimbursement purposes, including the 

MDPP benefit. Participation in the DPRP 

is voluntary, data are de-identified, no 

personally identifiable information (PII) 

is collected by CDC, and there are no 

costs to respondents other than their 

time. CDC is requesting a three-year 

revised approval. The total estimated 

annual burden hours requested is 7,400. 

ESTIMATED ANNUALIZED BURDEN HOURS FOR NEW ORGANIZATIONS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Avg. burden 

per response 

(in hours) 

Total burden 

(in hours) 

Public sector organizations that deliver the National DPP lifestyle change program.DPRP Application Form ...........

DPRP Evaluation Data ............

80 

680 

1 

2 

1 

2 

80 

2,720 

Private sector organizations that deliver the 

National DPP lifestyle change program.

DPRP Application Form ...........

DPRP Evaluation Data ............

120 

1,120 

1 

2 

1 

2 

120 

4,480 

Total ............................................................ .................................................. .................... ........................ ........................ 7,400 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2023–27550 Filed 12–14–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–1186; Docket No. CDC–2023– 

0099] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled Information 

Collection for Tuberculosis Data from 

Referring Entities to CureTB. The 

CureTB program works to prevent the 

spread of tuberculosis (TB) among 

people who cross international borders 

by providing linkage to care for patients 

with active/suspected TB when they 

leave the U.S., accurate and up-to-date 

information for receiving providers, 

motivation and resources for mobile 

individuals to continue care, linkage for 

comorbidities, and facilitation of 

positive outcomes and communication 

between partners. 

DATES: CDC must receive written 

comments on or before February 13, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0099 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Information Collection for 

Tuberculosis Data from Referring 

Entities to CureTB (OMB Control No. 

0920–1186, Exp. 2/29/2024)— 

Extension—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

The CureTB program at CDC works to 

prevent the spread of tuberculosis (TB) 

among people who cross international 

borders. To reduce disease transmission 

and the emergence of drug-resistant TB, 


ddrumheller on DSK120RN23PROD with NOTICES1
86904 Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 

CureTB connects people with TB to 

healthcare services as they move 

between the United States and other 

countries. The program is a 

collaboration between CDC’s Division of 

Global Migration Health (DGMH) and 

the County of San Diego’s Tuberculosis 

Control Program. CureTB collaborates 

with health authorities throughout the 

United States and around the world to 

link people with TB to care at their 

destinations. Health departments, 

healthcare providers, and others seeking 

help in linking patients to ongoing TB 

care in other countries can refer patients 

to CureTB. CureTB has an interagency 

agreement with ICE (Immigration and 

Custom Enforcement) to refer those 

patients with suspected or confirmed 

TB when they are repatriated to their 

countries of origin. 

CureTB collects the following types of 

information: (1) referring entities 

(referring agency and jurisdiction) 

information including name of referring 

person, telephone numbers, fax 

numbers, email addresses; (2) patient’s 

name and last name(s), demographics 

date of birth, gender, address (U.S. and 

outside of the U.S), telephone numbers, 

email address, patient’s contact persons 

including name and telephone number; 

and (3) TB clinical information, 

including diagnostic testing (radiology 

reports, laboratory testing reports, other 

diagnostic methods used, treatment 

regimen and information about 

comorbidities). 

CDC is requesting OMB approval for 

an additional three years. CDC requests 

approval for an estimated 1,125 annual 

burden hours. There is not cost to 

respondents other than their time to 

participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

U.S. health departments ........................... CureTB Transnational Notification ........... 80 4 30/60 160 

TB patients referred by U.S. health departments.CureTB Transnational Notification ........... 214 1 5/60 18 

Tb patients referred by ICE ...................... CureTB Transnational Notification ........... 587 1 45/60 440 

TB treating physicians in new country ...... CureTB Clinician Public Health Department Follow-up Script.870 3 10/60 435 

U.S. health departments ........................... CureTB Contact/Source Investigation (CI/ 

CS) Notification.

20 5 30/60 50 

U.S. health departments ........................... CureTB Program Partner Satisfaction Assessment Questionnaire 1.100 1 10/60 17 

U.S. health departments ........................... CureTB Program Partner Satisfaction Assessment Questionnaire 2.50 1 6/60 5 

Total ................................................... ................................................................... .................... ........................ .................... 1,125 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2023–27549 Filed 12–14–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–1800–N2] 

Inflation Reduction Act (IRA) Revised 

Program Guidance 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

the availability of CMS’ revised 

guidance for the Medicare Part B and 

Part D Prescription Drug Inflation 

Rebate Program for the implementation 

of the Inflation Reduction Act. CMS will 

be releasing additional Inflation 

Reduction Act-related guidance; all can 

be viewed on the dedicated Inflation 

Reduction Act section of the CMS 

website. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries related to the revised guidance 

should be sent to IRARebateand 

Negotiation@cms.hhs.gov with the 

relevant subject line, ‘‘Medicare 

Inflation Rebate Program Guidance.’’ 

SUPPLEMENTARY INFORMATION: The 

Inflation Reduction Act was signed into 

law on August 16, 2022. Section 11101 

of the Inflation Reduction Act added a 

new section 1847A(i) to the Social 

Security Act (the Act), which 

establishes a requirement for 

manufacturers to pay Medicare Part B 

rebates for single source drugs and 

biological products with prices that 

increase faster than the rate of inflation 

for a calendar quarter to the Federal 

Supplementary Medical Insurance Trust 

Fund, and provides for lower Part B 

beneficiary cost sharing on these drugs 

and biologicals. Section 11102 of the 

Inflation Reduction Act added a new 

section 1860D–14B to the Act, which 

establishes a requirement for 

manufacturers to pay rebates to the 

Federal Supplementary Medical 

Insurance Trust Fund for certain Part D 

drugs when prices increase faster than 

the rate of inflation for each 12-month 

applicable period. Collectively, this 

program to implement these rebates is 

referred to as the Medicare Prescription 

Drug Inflation Rebate Program, or the 

Inflation Rebate Program. 

To obtain copies of the revised 

guidance and the responses to 

comments from the initial guidance, as 

well as other Inflation Reduction Actrelated documents, please access the 

CMS Inflation Reduction Act website by 

copying and pasting the following web 

address into your web browser: https:// 

www.cms.gov/inflation-reduction-actand-medicare. If interested in receiving 

CMS Inflation Reduction Act updates by 

email, individuals may sign up for CMS 

Inflation Reduction Act’s email updates 

at https://www.cms.gov/About-CMS/ 

Agency-Information/Aboutwebsite/

EmailUpdates. 

The Administrator of the Centers for 

Medicare & Medicaid Services (CMS), 

Chiquita Brooks-LaSure, having 

reviewed and approved this document, 

authorizes Vanessa Garcia, who is the 

Federal Register Liaison, to 

electronically sign this document for 


ddrumheller on DSK120RN23PROD with NOTICES1